- Conditions
- Advanced Solid Tumors, Non-small Cell Lung Cancer
- Interventions
- BMS-986442, Nivolumab, Docetaxel, Carboplatin, Pemexetred, Paclitaxel
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Costa Mesa, California • Orange, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 381
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Drug · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- AZD6244, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • New York, New York + 1 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- RAD001 (in addition to standard radiation and chemotherapy)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
- Interventions
- talabostat, pemetrexed
- Drug
- Lead sponsor
- Point Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 84 more
- Conditions
- Head and Neck Cancer
- Interventions
- oxaliplatin, pemetrexed disodium
- Drug
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 7
- States / cities
- Owensboro, Kentucky • Paducah, Kentucky • Jackson, Tennessee + 1 more
- Conditions
- Mesothelioma
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 7 more
- Conditions
- Esophageal Cancer
- Interventions
- carboplatin, Pemetrexed, conventional surgery, neoadjuvant therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 90
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
- Conditions
- Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- Durvalumab, Surgery, Radiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Lowell, Massachusetts + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, HER3-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Fargo, North Dakota + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Concord, California + 46 more
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-02341066, Pemetrexed, Docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 119
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Fayetteville, Arkansas • Duarte, California • Fountain Valley, California + 29 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
- Conditions
- Solid Tumors
- Interventions
- ORIC-114, Chemotherapy drug
- Drug
- Lead sponsor
- ORIC Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • Huntington Beach, California • Irvine, California + 14 more
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI
- Drug · Radiation · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more
- Conditions
- Lung Cancer
- Interventions
- cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 40
- States / cities
- Downy, California • Fountain Valley, California • Fullerton, California + 37 more
- Conditions
- Locally Advanced Non-small Cell Lung Cancer
- Interventions
- vorinostat
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Philadelphia, Pennsylvania • Charleston, South Carolina